Merck Teams With Hanwha to Develop Biosimilar Enbrel

Merck is teaming up with Korean firm Hanwha Chemical to develop a biosimilar form of Pfizer and Amgen’s TNF-blocker, Enbrel (etanercept), which has a patent expiry date looming in October 2012. The collaboration will focus on Hanwha’s HD203 candidate, which is currently undergoing a Phase III trial in Korea.
Genetic Engineering & Biotechnology News